- Home
- MESO vs DGII Comparison
MESO vs DGII Comparison
Compare MESO & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MESO
- DGII
- Stock Information
- Founded
- MESO 2004
- DGII 1985
- Country
- MESO Australia
- DGII United States
- Employees
- MESO 81
- DGII N/A
- Industry
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- DGII Computer peripheral equipment
- Sector
- MESO Health Care
- DGII Technology
- Exchange
- MESO Nasdaq
- DGII Nasdaq
- Market Cap
- MESO 2.0B
- DGII 1.3B
- IPO Year
- MESO N/A
- DGII N/A
- Fundamental
- Price
- MESO $15.60
- DGII $35.63
- Analyst Decision
- MESO Buy
- DGII Buy
- Analyst Count
- MESO 2
- DGII 4
- Target Price
- MESO $24.00
- DGII $38.75
- AVG Volume (30 Days)
- MESO 213.4K
- DGII 126.4K
- Earning Date
- MESO 08-28-2025
- DGII 11-12-2025
- Dividend Yield
- MESO N/A
- DGII N/A
- EPS Growth
- MESO N/A
- DGII 147.46
- EPS
- MESO N/A
- DGII 1.14
- Revenue
- MESO $17,198,000.00
- DGII $420,935,000.00
- Revenue This Year
- MESO $288.50
- DGII $2.46
- Revenue Next Year
- MESO $167.17
- DGII $7.51
- P/E Ratio
- MESO N/A
- DGII $31.75
- Revenue Growth
- MESO 191.39
- DGII N/A
- 52 Week Low
- MESO $8.34
- DGII $22.39
- 52 Week High
- MESO $22.00
- DGII $39.62
- Technical
- Relative Strength Index (RSI)
- MESO 39.64
- DGII 39.37
- Support Level
- MESO $16.10
- DGII $37.46
- Resistance Level
- MESO $16.91
- DGII $38.95
- Average True Range (ATR)
- MESO 0.50
- DGII 1.05
- MACD
- MESO -0.27
- DGII -0.38
- Stochastic Oscillator
- MESO 0.60
- DGII 13.64
About MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.